Delivery Order SPE2DB22D1017-SPE2DB25FG9EQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,913.51 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) with an ultimate completion date of August 12, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $13,132.00 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,533.49 to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed price delivery order was competitively awarded without any set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply transaction within DLA's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-tablet units, with a contract ceiling value of $13,740.06. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,093.90 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was utilized for this award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $60,140.57 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The contract requires performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside provisions applied to the award. This...
- The Defense Logistics Agency awarded a delivery order valued at $20,512.96 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $10,862.72 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) with a firm fixed-price structure. This non-set-aside competitive award was issued on May 30, 2025, with an ultimate completion date of June 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $9,112.43 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xeljanz 5 mg tablets (60-count units). This is a firm fixed-price contract with an ultimate completion date of September 5, 2025, and represents a non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,059.18 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, PA....
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9EQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,568.39 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery against the vendor's existing Indefinite Delivery Contract (IDC). The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's primary IDC with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. This contract serves as a global pharmaceutical support mechanism enabling the company to supply an extensive range of medications, vaccines, and medical supplies to military healthcare programs and the Defense Health Agency. The delivery of Xeljanz, a specialty pharmaceutical used for rheumatoid arthritis and other inflammatory conditions, exemplifies the vendor's role as a critical supplier of brand-name pharmaceuticals within the federal medical supply chain supporting military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.6k | 8/7/25 |